Modeling Pharmacodynamic Response to the Poly(ADP-Ribose) Polymerase Inhibitor ABT-888 in Human Peripheral Blood Mononuclear Cells

Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers

(2011) Tomasz Zaremba et al.   BIOCHEMICAL JOURNAL

Histone  H2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers

(2010) C. E. Redon et al.   CLINICAL CANCER RESEARCH

The statistics of phase 0 trials

(2010) Larry V. Rubinstein et al.   STATISTICS IN MEDICINE

Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines

(2009) T Zaremba et al.   BRITISH JOURNAL OF CANCER

Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies

(2009) Shivaani Kummar et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors

(2008) Xuesong Liu et al.   ANALYTICAL BIOCHEMISTRY

Preclinical Modeling of a Phase 0 Clinical Trial: Qualification of a Pharmacodynamic Assay of Poly (ADP-Ribose) Polymerase in Tumor Biopsies of Mouse Xenografts

(2008) R. J. Kinders et al.   CLINICAL CANCER RESEARCH